TOP 20 Archives - Page 4 of 12

TOP 20

Top 20 Nutraceutical Companies of 2024

Shots:Nutraceuticals offer miraculous health benefits by enhancing body function and assisting in body repair and growthIn 2023, the global Nutraceuticals market was valued at $419.93B and is expected to increase from $457.35B in 2024 to $976.74B by 2032 with a CAGR of 9.95 percent. Nestlé ranks first on our list with reported segment…

June 6, 2024

Top 20 Diagnostic Companies of 2024 

Shots:  Propelled by unceasing innovations and inch-perfect precision, the diagnostic industry is advancing at an astonishing pace In 2023, the global diagnostic test market size was valued at $210.58B and is envisioned to reach $284.38B by 2033, registering a CAGR of 3.05 percent from 2024 to 2033. Roche reclaims its first position with a revenue…

May 23, 2024

Top 20 Medical Device Companies of 2024 

Shots:  Bringing innovation and technology to healthcare, the MedTech sector is growing rapidly and transforming the ways diagnosis and treatment are received With a global market size of $503.2B in 2023, the MedTech sector anticipates reaching $776.4B by 2033 with a CAGR of 4.4 percent. With a staggering revenue of $32.31B, Medtronic ranks first in…

May 9, 2024

Top 20 RNAi Therapeutic Companies of 2024

Shots: RNAi therapeutics are innovative medications that enable rapid identification of specific inhibitors of disease targets across a wide range of molecule classes. Several biopharma companies are investing in RNAi therapeutics extravagantly to maintain a healthy foothold in innovative medicines In 2023, the global RNAi drug delivery market size was valued at $84.1B and is…

April 25, 2024

Top 20 Biopharma Deal Terminations of 2023 Based on Total Deal Value

Shots: Sticking to M&A and licensing agreements can be really challenging, especially when dealing with stringent antitrust laws and evolving regulatory challenges. In such adverse scenarios, the rational and right step seems to be nullifying the existing deals.In 2023, the termination of the deal between Janssen and Arrowhead remained the talk of the town…

April 18, 2024

Top 20 Biopharma Companies of 2024

Shots:Driven by innovations and propelled by the pursuit of delivering the best-in-class therapies, 2023 remained a good year for the Biopharma Industry, despite a slight revenue decline, partly due to the conclusion of the COVID-19 pandemicWith a CAGR of 7.8 %, the global biopharma industry is anticipated to register a market size of…

April 11, 2024

Top 20 IPOs in Healthcare by Total Fund Value 2023

Shots:Clinical-stage biopharma companies are in constant need of funding and the best way to pull in money in such dire situations is by going public. 2023 had been a great year for Wall Streets across the globe with continuous announcements of IPOsKenvue by bagging $4.37B upon completion of its IPO ranked first in…

March 28, 2024

Top 20 Women Health Focusing Companies of 2024 Based on Market Cap

Shots:While the World celebrated International Women’s Day, PharmaShots was busy preparing an exciting report on the Top 20 Women Health Focusing Companies Based on Market CapWomen's Health Market size was valued at $38.10B in 2023 and is expected to register $58.10B by 2030 with a CAGR of 4.9 percent. AbbVie managed to secure…

March 14, 2024

Top 20 Radiopharma Companies of 2024 Based on Market Cap

Shots:With diverse applications in diagnostic imaging, theragnostics, and targeted therapy, radiopharmaceuticals are gradually tapping into an ocean of unlimited opportunitiesBy 2030, the radiopharmaceutical market size is expected to grow to $12.18B. In 2023, POINT Biopharma topped the list among radiopharma companies with a market cap of $726.88B followed by Novartis with a market…

February 28, 2024

Top 20 Life Sciences Deals of 2023 by Total Deal Value

Shots: Driven by mutual growth and expansion, strategic collaborations are embedded deeply in the modus operandi of life sciences deals. In 2023, the volume of life science deals was comparatively high vs. 2022 The collaboration deal between Daiichi Sankyo and Merck & Co. for $22B ranks first in our list followed by the development and…

February 15, 2024